DKSH and FrontierView Publish Whitepaper on Southeast Asia as a Growth Accelerator for Global Healthcare Firms
DKSH and FrontierView, a business intelligence and advisory firm, published a whitepaper providing an in-depth assessment of the healthcare status of the Southeast Asia (SEA) region. The research collated in DKSH's whitepaper provides a comprehensive analysis of the regional healthcare landscape, the challenges and abundant opportunities present, as well as recommended actions for...
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Today at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place at the Walter E. Washington Convention Center in Washington, DC, investigators from Gifu Heart Center and Fukuoka Sanno Hospital presented the...
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., Oct. 26, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for the Phase I/IIa Study of RXRG001 (SPRINX-1 Study) on October 25th, 2024. RXRG001 is the first-ever circular RNA therapy...
KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)
SAN FRANCISCO, Oct. 26, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 in the treatment of...
WOORIEN launches ‘MyVet CT Plus’: Advanced Veterinary imaging Solution
Lowering CT barriers and improving diagnostic quality Spiral-Linear Technology with Enhanced Power Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, proudly announces the launch of 'MyVet CT Plus'. MyVet CT Plus is the successor of 'MyVet CT i3D',...
Lifezoom Unveils Next-Gen 3-in-1 Handheld Red Light Therapy Wand – Transform Your Skincare Routine
NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Lifezoom, a new force in red light therapy with strong R&D capabilities, is about to launch its handheld red light therapy wand, its newest device, as a declaration of its high-end brand route and also shows its determination of providing users with safer and more effective treatment solutions. Introduction to Lifezoom's Handheld Red Light Therapy...
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a...
Prudential launches first-in-market insurtech solutions MedScreen+ with Reinsurance Group of America
HONG KONG, Oct. 25, 2024 /PRNewswire/ -- Prudential Hong Kong Limited ("Prudential") is proud to be the first insurer in Hong Kong to launch MedScreen+, an innovative digital underwriting tool developed in collaboration with Reinsurance Group of America, Incorporated ("RGA"), a leading global life and health reinsurer. The launch of MedScreen+ exemplifies Prudential's...
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycobacterial (NTM) infections. Details and Results of the Phase I Clinical Trial in Australia...
Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF...
